Merck already got one thing wrong... At their Analyst Day, they inferred the second interim would lead to them filing for an NDA. Didn't happen. Merck's failed at plenty of trials. Maybe Merck paid Ariad $70 million, not for sarcoma, but because their IGF1R inhibitor won't work well unless combined with an mTOR inhibitor.
Market Data 
Markets
AI
